Melior’s tolimidone succeeds in phase 2b trial in Type 2 diabetes

This article was originally published here

According to the company, tolimidone significantly reduced HbA1c in comparison to placebo in the mid-stage trial as per the analysis of all patients who were subjected to the

The post Melior’s tolimidone succeeds in phase 2b trial in Type 2 diabetes appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply